At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 10 target
Drug / intervention
YUVA-GT-F901biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Lentiviral FIX Gene Therapy for Hemophilia B
In Brief
A Phase 1 clinical trial evaluating YUVA-GT-F901 for Hemophilia B. Currently recruiting, targeting 10 participants across 1 site.
Detailed Summary
This study is a Phase I trial using an advanced lentiviral vector to deliver a functional gene for human clotting factor IX into patients with hemophilia B, to evaluate the safety and efficacy of infusion of lentiviral gene modified autologous stem cells in patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHemophilia B
CountriesChina
Collaborators--
Timeline
Phase 1Recruiting
202020212022202320242025202620272028
First PostedMay 2019
Enrollment StartJun 2025
TodayJul 2026
Primary CompletionMay 2027
Study CompletionJun 2028
First PostedMay 23, 2019
Enrollment StartJun 1, 2025
Primary CompletionMay 31, 2027
Study CompletionJun 1, 2028
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 7.1 years agoPrimary completion in 11 months
Interventions
YUVA-GT-F901biological
Lentiviral factor IX gene modified autologous hematopoietic and mesenchymal stem cells